Oxford Global NextGen Omics UK 2024

Tradeshow/Conference
Novotel London West, Hammersmith

Explore NextGen Omics 2024: Unlocking Future Insights in Multi-Omics Research. Join 700+ leaders, experts and researchers at Oxford Global’s flagship NextGen Omics 2024, featuring the 16th Annual NGS & Clinical Diagnostics Congress, 12th Annual Single Cell & Spatial Analysis Congress and 6th Annual Digital PCR & Liquid Biopsies Congress and CRISPR-Based Medicine Congress.

Meet the NanoString, now Bruker Spatial Biology team at booth #49.

Sponsored Workshop | Wednesday 25th October | 14:00 – 17:00 | CONFERENCE ROOM 1

Unlock the potential of your samples with the GeoMx® Digital Spatial Profiler and CosMx™ Spatial Molecular Imager

  • Obtain new ideas, approaches and lessons learned relating to spatial transcriptomics to better understand how to apply spatial technologies in your research. Achieve multicellular analysis with GeoMx® Digital Spatial Profiler, or zoom in to view single cells with the CosMx™ Spatial Molecular Imager (SMI).
  • Hear from current users about insights they have gained by unravelling biological complexity using spatial technologies.
  • Analyzing Spatial Data: Learn how to evaluate spatial performance of single cell spatial imaging technologies to deliver more biological information with high quality data. Gain spatial biology insights anytime, anywhere using AtoMx™ Spatial Informatics Platform (SIP), a cloud-based solution that provides advanced data analytics and global collaboration capabilities.

AGENDA

  1. Introduction to Bruker Spatial Biology GeoMx DSP and CosMx SMI | Christoph Koenig, NanoString a Bruker Company
  2. Joshua Harvey, Postdoctoral Research Associate, University of Exeter, “Spatial transcriptomics to resolve neuronal dysfunction in Alzheimer’s disease
  3. Scott Hoffmann, Associate Director, Astra Zeneca, “Integration of global proteomic and spatial transcriptomic data for novel insights in pre-clinical drug development
  4. Panel Discussion “The future of Spatial Multiomics” – All
In-event presentation | Thursday 24th October | 11:40 – 12:05 | CONFERENCE ROOM 2

Identifying Early Signs Of Cancer Initiation In Histologically Normal Breast Tissue To Improve Risk Assessment Of Germline BRCA 1/2 Mutation Carriers

An AI-driven spatial transcriptomic study on gBRCA1/2 mutation carriers aiming to uncover molecular insights into tissue heterogeneities and accelerated aging, using H&E-stained whole slide images to develop personalised breast cancer risk assessments.

Speakers

Christoph König

Senior Product Application Scientist, NanoString

Scott Hoffman

Associate Director, Astra Zeneca

Joshua Harvey

Postdoctoral Research Associate & Alzheimer's Research UK ECR Representative, University of Exeter

Fatima Mohamed

PhD Student, Cancer Bioinformatics & Causal Explainability Group, King’s College London